MiNK Therapeutics
MiNK Therapeutics is a clinical-stage company developing innovative allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. They focus on off-the-shelf therapies that enhance immunity and have treated over 70 patients with solid tumors and severe acute respiratory distress syndrome. The company leverages proprietary technology platforms for cell manufacturing, engineering, and discovery, aiming to deliver living medicines at scale. Their leadership includes experts in immunology, cell therapy, and biotech industry, and they are actively involved in clinical trials, research publications, and collaborations to advance their pipeline of iNKT cell therapies.
Industries
Nr. of Employees
small (1-50)
MiNK Therapeutics
Lexington, Massachusetts, United States
Patents
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
US-12391741-B2
View DetailsT cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
US-11718658-B2
View Details
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
US-12391741-B2
View DetailsT cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
US-11718658-B2
View DetailsProducts
AGENT-797 (allogeneic iNKT cell therapy)
An off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapy candidate in clinical development for solid tumors, multiple myeloma, ARDS and other indications.
Engineered FAP-targeting CAR iNKT (MiNK-215)
Preclinical armored CAR iNKT product targeting fibroblast activation protein (FAP) designed to modulate tumor stroma and enhance anti-tumor immunity.
BCMA-targeting CAR iNKT (MiNK-413)
Preclinical BCMA-directed armored CAR iNKT candidate intended for hematologic malignancies; reported IND-ready status in disclosures.
PRAME-targeting TCR iNKT (MiNK-PRAME-TCR)
Preclinical TCR-engineered iNKT candidate targeting PRAME for solid tumor indications; candidate nomination reported.
iNKT bispecific engagers (discovery stage)
Discovery-stage program to generate IgG-based bispecific engager molecules designed to recruit and activate iNKT cells against tumor targets.
AGENT-797 (allogeneic iNKT cell therapy)
An off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapy candidate in clinical development for solid tumors, multiple myeloma, ARDS and other indications.
Engineered FAP-targeting CAR iNKT (MiNK-215)
Preclinical armored CAR iNKT product targeting fibroblast activation protein (FAP) designed to modulate tumor stroma and enhance anti-tumor immunity.
BCMA-targeting CAR iNKT (MiNK-413)
Preclinical BCMA-directed armored CAR iNKT candidate intended for hematologic malignancies; reported IND-ready status in disclosures.
PRAME-targeting TCR iNKT (MiNK-PRAME-TCR)
Preclinical TCR-engineered iNKT candidate targeting PRAME for solid tumor indications; candidate nomination reported.
iNKT bispecific engagers (discovery stage)
Discovery-stage program to generate IgG-based bispecific engager molecules designed to recruit and activate iNKT cells against tumor targets.
Services
Partnerships for discovery, preclinical development, clinical development and access to investigational medicines, including flexible partnering approaches and external CMC support.
Partnerships for discovery, preclinical development, clinical development and access to investigational medicines, including flexible partnering approaches and external CMC support.
Expertise Areas
- Allogeneic cell therapy development
- Clinical trial management for cell therapies
- GMP biomanufacturing and CMC process development
- CAR and TCR discovery and engineering
Key Technologies
- Allogeneic iNKT cell therapeutics
- Chimeric antigen receptors (CARs)
- T cell receptor (TCR) engineering
- Bispecific cell-engagers
News & Updates
MiNK Therapeutics will present three abstracts on their innovative allogeneic iNKT cell programs at the Society for Immunotherapy of Cancer (SITC) 2024 conference.
Initial trial suggests invariant natural killer cell therapy improves survival in ARDS patients.
MiNK's allogeneic off-the-shelf invariant natural killer T-cell therapy, agenT-797, was well-tolerated and improved survival in COVID-19-associated ARDS patients.
MiNK Therapeutics believes its new cell therapy could eventually replace chemotherapy with a less invasive treatment.
A Massachusetts company is developing technology that could make chemotherapy obsolete.
Biomarker analysis from a phase 2 study of agenT-797 combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer.
MiNK Therapeutics will present three abstracts on their innovative allogeneic iNKT cell programs at the Society for Immunotherapy of Cancer (SITC) 2024 conference.
Initial trial suggests invariant natural killer cell therapy improves survival in ARDS patients.
MiNK's allogeneic off-the-shelf invariant natural killer T-cell therapy, agenT-797, was well-tolerated and improved survival in COVID-19-associated ARDS patients.
MiNK Therapeutics believes its new cell therapy could eventually replace chemotherapy with a less invasive treatment.
A Massachusetts company is developing technology that could make chemotherapy obsolete.
Biomarker analysis from a phase 2 study of agenT-797 combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer.